Cargando…

Association of response endpoints with survival outcomes in multiple myeloma

Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. These improvements have afforded more robust analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lonial, S, Anderson, K C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918869/ https://www.ncbi.nlm.nih.gov/pubmed/23868105 http://dx.doi.org/10.1038/leu.2013.220

Ejemplares similares

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
por: Miller, A, et al.
Publicado: (2017)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
por: Richardson, Paul G., et al.
Publicado: (2023)

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
por: Wang, Dongxue, et al.
Publicado: (2017)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

Systematic review of outcomes and endpoints in preventive migraine clinical trials
por: McGinley, James S., et al.
Publicado: (2021)

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Long-term survival in multiple myeloma
por: João, Cristina, et al.
Publicado: (2014)

A novel event-free survival endpoint in locally advanced pancreatic cancer
por: Hammel, Pascal, et al.
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Calcium affects on vascular endpoints
por: Patel, Vaishali B, et al.
Publicado: (2012)

Choroideremia: The Endpoint Endgame
por: Abdalla Elsayed, Maram E. A., et al.
Publicado: (2023)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Multiple Myeloma Associated Bone Disease
por: Rasch, Stine, et al.
Publicado: (2020)

Multiple myeloma
por: Collins, Conor D.
Publicado: (2010)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
por: Chen, Tianzeng, et al.
Publicado: (2022)

Assessment tools for patient-reported outcomes in multiple myeloma
por: Wang, Ting, et al.
Publicado: (2023)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
por: Popat, Rakesh, et al.
Publicado: (2023)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Deep Response in Multiple Myeloma: A Critical Review
por: Fulciniti, Mariateresa, et al.
Publicado: (2015)

What Is Performance? A Scoping Review of Performance Outcomes as Study Endpoints in Athletics
por: Raysmith, Benjamin P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sf9657dir46p84isbum682bnb8